MX2022016218A - Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4.Info
- Publication number
- MX2022016218A MX2022016218A MX2022016218A MX2022016218A MX2022016218A MX 2022016218 A MX2022016218 A MX 2022016218A MX 2022016218 A MX2022016218 A MX 2022016218A MX 2022016218 A MX2022016218 A MX 2022016218A MX 2022016218 A MX2022016218 A MX 2022016218A
- Authority
- MX
- Mexico
- Prior art keywords
- ctla
- antibody
- antibodies
- formulations containing
- containing anti
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 2
- 102000043321 human CTLA4 Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049540P | 2020-07-08 | 2020-07-08 | |
| PCT/US2021/040648 WO2022010988A1 (en) | 2020-07-08 | 2021-07-07 | Stabilized formulations containing anti-ctla-4 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016218A true MX2022016218A (es) | 2023-03-31 |
Family
ID=77207237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016218A MX2022016218A (es) | 2020-07-08 | 2021-07-07 | Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220031843A1 (enExample) |
| EP (1) | EP4178983A1 (enExample) |
| JP (1) | JP2023533963A (enExample) |
| KR (1) | KR20230035595A (enExample) |
| CN (1) | CN115812080A (enExample) |
| AU (1) | AU2021305093A1 (enExample) |
| CA (1) | CA3185091A1 (enExample) |
| IL (1) | IL299152A (enExample) |
| MX (1) | MX2022016218A (enExample) |
| WO (1) | WO2022010988A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11525629B2 (en) | 2020-02-04 | 2022-12-13 | Regeneron Pharmaceuticals, Inc. | Target residual moisture content for lyophilized drug product |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| KR101867279B1 (ko) * | 2010-10-06 | 2018-06-15 | 리제너론 파아마슈티컬스, 인크. | 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형 |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| MY164611A (en) * | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| EP2633874A1 (en) * | 2012-03-02 | 2013-09-04 | Sanofi-Aventis Deutschland GmbH | Fixed-dose medicament delivery device |
| AR092325A1 (es) * | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| NZ735820A (en) * | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| MA50501A (fr) * | 2017-05-02 | 2020-09-09 | Merck Sharp & Dohme | Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| EP4082572A4 (en) * | 2019-12-25 | 2024-03-06 | Bio-Thera Solutions, Ltd. | ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD AND ITS APPLICATION |
-
2021
- 2021-07-07 AU AU2021305093A patent/AU2021305093A1/en active Pending
- 2021-07-07 IL IL299152A patent/IL299152A/en unknown
- 2021-07-07 MX MX2022016218A patent/MX2022016218A/es unknown
- 2021-07-07 EP EP21749919.3A patent/EP4178983A1/en active Pending
- 2021-07-07 US US17/369,321 patent/US20220031843A1/en not_active Abandoned
- 2021-07-07 CN CN202180049075.7A patent/CN115812080A/zh active Pending
- 2021-07-07 JP JP2023501015A patent/JP2023533963A/ja active Pending
- 2021-07-07 KR KR1020237003824A patent/KR20230035595A/ko active Pending
- 2021-07-07 WO PCT/US2021/040648 patent/WO2022010988A1/en not_active Ceased
- 2021-07-07 CA CA3185091A patent/CA3185091A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115812080A (zh) | 2023-03-17 |
| CA3185091A1 (en) | 2022-01-13 |
| WO2022010988A1 (en) | 2022-01-13 |
| IL299152A (en) | 2023-02-01 |
| JP2023533963A (ja) | 2023-08-07 |
| EP4178983A1 (en) | 2023-05-17 |
| AU2021305093A1 (en) | 2023-03-09 |
| KR20230035595A (ko) | 2023-03-14 |
| US20220031843A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552092A1 (en) | Stabilized formulations containing anti-il-33 antibodies | |
| PH12019502123A1 (en) | Stable antibody formulation | |
| Sheppard et al. | Tocilizumab (actemra) | |
| Voltarelli et al. | Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus | |
| Zhang et al. | Soluble CR1 therapy improves complement regulation in C3 glomerulopathy | |
| JP5490714B2 (ja) | タンパク質製剤 | |
| KR101299599B1 (ko) | Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물 | |
| JP4340062B2 (ja) | 粘度の減少した濃縮タンパク質製剤 | |
| CN102414221A (zh) | 抗体配制剂 | |
| CY1121420T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| TN2009000382A1 (en) | Stable antibody formulations | |
| Segovia et al. | A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study | |
| KR20220148329A (ko) | 항체 제제 | |
| KR20210120048A (ko) | 다발성 골수종의 치료 방법 | |
| Rieger et al. | Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia. | |
| HUE035619T2 (en) | Stabilization of polypeptides | |
| Efe et al. | A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models | |
| ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| MX2022016218A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. | |
| Kasikis et al. | Current and emerging targeted therapies for acute graft versus host disease | |
| Zhang et al. | Formulation strategies in immunotherapeutic pharmaceutical products | |
| US20230357406A1 (en) | Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof | |
| MX2022008949A (es) | Formulacion de anticuerpos estable. | |
| Zhang et al. | WJCO |